Please assess the completion status of the following clinical trial:

Trial Title: Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Written informed consent prior to participation~* Female and male patients 18 years of age or older with a diagnosis of non-valvular atrial fibrillation.~* At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke prevention prior to baseline assessment.~* Patients switched to Pradaxa® according to Summary of Product Characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community.~Exclusion criteria:~* Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC)~* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in non-valvular atrial fibrillation.~* Current participation in any clinical trial of a drug or device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: None): Patients switched from vitamin K antagonist (VKA) to dabigatran

Based on this trial design, predict the completion outcome and termination type (if applicable).